Seema A. Bhat, MD

Seema A. Bhat, MD, discusses selecting between liso-cel and pirtobrutinib in relapsed/refractory CLL.

Seema A. Bhat, MD, discusses disease features and patient characteristics that inform the choice between pirtobrutinib and liso-cel for CLL.

Seema A. Bhat, MD, discusses the ongoing development of BTK degraders and novel bispecific antibodies in relapsed/refractory CLL.

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.